BRF2 and cancer: BRF2 has been shown to be highly overexpressed in a variety of cancers including gastric, kidney, and melanoma cancers [28], and our previous studies have pointed out that BRF2 protein overexpression is common in early-stage ESCC and significantly correlated with tumor prognosis and relapse [29].